Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

Схожие документы

• Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
  по: Philip J. Mease, и др.
  Опубликовано: (2015)
• Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis
  по: Désirée van der Heijde, и др.
  Опубликовано: (2016)
• Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis
  по: van der Heijde, Désirée, и др.
  Опубликовано: (2016)
• Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study
  по: McInnes, Iain B, и др.
  Опубликовано: (2017)
• Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study
  по: Iain B. McInnes, и др.
  Опубликовано: (2017)